Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-DR4/TRAIL R1 Antibody (6F81) is a Mouse antibody targeting DR4/TRAIL R1. Anti-DR4/TRAIL R1 Antibody (6F81) can be used in ELISA(Cap),FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μL | $70 | 7-10 days | |
100 μL | $199 | 7-10 days |
Description | Anti-DR4/TRAIL R1 Antibody (6F81) is a Mouse antibody targeting DR4/TRAIL R1. Anti-DR4/TRAIL R1 Antibody (6F81) can be used in ELISA(Cap),FCM. |
Alias | tumor necrosis factor receptor superfamily member 10a, TRAILR-1, TRAILR1, TNFRSF10A, MGC9365, DR4, CD261, APO2 |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 6F81 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human TNFRSF10A(CD261) expression on HeLa cells. Cells were stained with purified anti-Human TNFRSF10A(CD261), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | ELISA(Cap),FCM |
Recommended Dose | FCM: 1:25-1:100; ELISA(Cap): 1:250-1:2000 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human TRAIL R1 / CD261 / TNFRSF10A (rh TRAIL R1 / CD261 / TNFRSF10A; TMPY-01720; NP_003835.2; Met1-Asn239). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Others Formats | FITC/PE |
Antibody Types Available | 3 |
Immunogen | Recombinant Human TRAIL R1 / CD261 / TNFRSF10A Protein (TMPY-01720) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.